JP2014532038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532038A5 JP2014532038A5 JP2014529893A JP2014529893A JP2014532038A5 JP 2014532038 A5 JP2014532038 A5 JP 2014532038A5 JP 2014529893 A JP2014529893 A JP 2014529893A JP 2014529893 A JP2014529893 A JP 2014529893A JP 2014532038 A5 JP2014532038 A5 JP 2014532038A5
- Authority
- JP
- Japan
- Prior art keywords
- butyl
- methoxy
- tert
- ethyl
- benzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 45
- -1 1-tert-butyl - butyl Chemical group 0.000 claims description 37
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 108020001756 ligand binding domains Proteins 0.000 claims description 17
- 239000000654 additive Substances 0.000 claims description 14
- LZWZPGLVHLSWQX-XMMPIXPASA-N n'-(3,5-dimethylbenzoyl)-n'-[(3r)-2,2-dimethylhexan-3-yl]-2-ethyl-3-methoxybenzohydrazide Chemical compound C=1C(C)=CC(C)=CC=1C(=O)N([C@H](CCC)C(C)(C)C)NC(=O)C1=CC=CC(OC)=C1CC LZWZPGLVHLSWQX-XMMPIXPASA-N 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 9
- 230000014509 gene expression Effects 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 6
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 108010057988 ecdysone receptor Proteins 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000019838 Blood disease Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000001276 controlling effect Effects 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000000749 insecticidal effect Effects 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- LZWZPGLVHLSWQX-DEOSSOPVSA-N n'-(3,5-dimethylbenzoyl)-n'-[(3s)-2,2-dimethylhexan-3-yl]-2-ethyl-3-methoxybenzohydrazide Chemical compound C=1C(C)=CC(C)=CC=1C(=O)N([C@@H](CCC)C(C)(C)C)NC(=O)C1=CC=CC(OC)=C1CC LZWZPGLVHLSWQX-DEOSSOPVSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532368P | 2011-09-08 | 2011-09-08 | |
| US61/532,368 | 2011-09-08 | ||
| PCT/US2012/054141 WO2013036758A1 (en) | 2011-09-08 | 2012-09-07 | Crystalline diacylhydrazine and the use thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015175584A Division JP6463237B2 (ja) | 2011-09-08 | 2015-09-07 | 結晶性ジアシルヒドラジンおよびその使用 |
| JP2018073426A Division JP6522826B2 (ja) | 2011-09-08 | 2018-04-05 | 結晶性ジアシルヒドラジンおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014532038A JP2014532038A (ja) | 2014-12-04 |
| JP2014532038A5 true JP2014532038A5 (enExample) | 2015-11-05 |
| JP6347745B2 JP6347745B2 (ja) | 2018-06-27 |
Family
ID=47832584
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529893A Expired - Fee Related JP6347745B2 (ja) | 2011-09-08 | 2012-09-07 | 結晶性ジアシルヒドラジンおよびその使用 |
| JP2015175584A Expired - Fee Related JP6463237B2 (ja) | 2011-09-08 | 2015-09-07 | 結晶性ジアシルヒドラジンおよびその使用 |
| JP2018073426A Active JP6522826B2 (ja) | 2011-09-08 | 2018-04-05 | 結晶性ジアシルヒドラジンおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015175584A Expired - Fee Related JP6463237B2 (ja) | 2011-09-08 | 2015-09-07 | 結晶性ジアシルヒドラジンおよびその使用 |
| JP2018073426A Active JP6522826B2 (ja) | 2011-09-08 | 2018-04-05 | 結晶性ジアシルヒドラジンおよびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8946294B2 (enExample) |
| EP (2) | EP2751072B1 (enExample) |
| JP (3) | JP6347745B2 (enExample) |
| KR (3) | KR102033138B1 (enExample) |
| CN (3) | CN106187812A (enExample) |
| AU (1) | AU2013201096B2 (enExample) |
| BR (1) | BR112014005509B1 (enExample) |
| CA (2) | CA3061802C (enExample) |
| DK (1) | DK2751072T3 (enExample) |
| ES (1) | ES2710212T3 (enExample) |
| IL (1) | IL231310B (enExample) |
| MX (3) | MX350158B (enExample) |
| PH (4) | PH12020551916A1 (enExample) |
| RU (1) | RU2629113C2 (enExample) |
| SG (2) | SG10201705596TA (enExample) |
| TW (1) | TWI586640B (enExample) |
| WO (1) | WO2013036758A1 (enExample) |
| ZA (1) | ZA201402010B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201705596TA (en) | 2011-09-08 | 2017-08-30 | Intrexon Corp | Crystalline diacylhydrazine and the use thereof |
| CA2959026C (en) * | 2014-08-22 | 2023-10-24 | Biocryst Pharmaceuticals, Inc. | Compositions and uses of amidine derivatives |
| US20180200209A1 (en) * | 2015-07-10 | 2018-07-19 | Millendo Therapeutics, Inc. | Enhanced bioavailability of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl)methyl)urea hydrochloride |
| US11002681B2 (en) * | 2015-12-02 | 2021-05-11 | Indian Institute Of Science | Method for rapid raman spectra detection of a single bacterium or group of bacterial species |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN108078969B (zh) * | 2017-12-25 | 2020-06-30 | 临沂大学 | 萘酰肼类化合物在制备抗微生物药物中的用途 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2707012B2 (ja) * | 1991-12-06 | 1998-01-28 | キッセイ薬品工業株式会社 | Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法 |
| US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| AU2002247214B2 (en) | 2001-02-20 | 2008-04-03 | Intrexon Corporation | Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
| ES2422303T3 (es) | 2001-02-20 | 2013-09-10 | Intrexon Corp | Receptores mutantes por sustitución novedosos y su uso en un sistema de expresión génica inducible basado en receptores nucleares |
| US7563879B2 (en) | 2001-09-26 | 2009-07-21 | Intrexon Corporation | Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| WO2003027266A2 (en) | 2001-09-26 | 2003-04-03 | Rheogene Holdings, Inc. | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| CA2477444A1 (en) | 2002-03-01 | 2003-09-12 | The Trustees Of Columbia University In The City Of New York | Reagents for asymmetric allylation, aldol, and tandem aldol and allylation reactions |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
| US7456315B2 (en) * | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| PT1663281E (pt) | 2003-08-29 | 2014-03-17 | Dyax Corp | Inibidores de proteases poli-peguilados |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| JP2009529542A (ja) | 2006-03-10 | 2009-08-20 | ダイアックス コーポレーション | エカランチドに関する配合物 |
| CA2689137C (en) * | 2007-05-29 | 2017-05-02 | Intrexon Corporation | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US20090098055A1 (en) * | 2007-08-23 | 2009-04-16 | Intrexon Corporation | Methods and Compositions for Diagnosing Disease |
| JP2010540534A (ja) * | 2007-09-28 | 2010-12-24 | イントレキソン コーポレーション | 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用 |
| JP2010539993A (ja) | 2007-10-08 | 2010-12-24 | イントレキソン コーポレーション | 遺伝子操作した樹状細胞および癌の治療のための使用 |
| BRPI0920679A2 (pt) | 2008-10-08 | 2022-05-17 | Intrexon Corp | Células construídas expressando múltiplos imunomoduladores e usos das mesmas |
| SG10201705596TA (en) * | 2011-09-08 | 2017-08-30 | Intrexon Corp | Crystalline diacylhydrazine and the use thereof |
-
2012
- 2012-09-07 SG SG10201705596TA patent/SG10201705596TA/en unknown
- 2012-09-07 PH PH1/2020/551916A patent/PH12020551916A1/en unknown
- 2012-09-07 CN CN201610518794.XA patent/CN106187812A/zh active Pending
- 2012-09-07 MX MX2014002629A patent/MX350158B/es active IP Right Grant
- 2012-09-07 CA CA3061802A patent/CA3061802C/en active Active
- 2012-09-07 SG SG11201400350VA patent/SG11201400350VA/en unknown
- 2012-09-07 PH PH1/2021/551061A patent/PH12021551061A1/en unknown
- 2012-09-07 KR KR1020147009225A patent/KR102033138B1/ko not_active Expired - Fee Related
- 2012-09-07 WO PCT/US2012/054141 patent/WO2013036758A1/en not_active Ceased
- 2012-09-07 EP EP12829775.1A patent/EP2751072B1/en active Active
- 2012-09-07 KR KR1020217015216A patent/KR20210069112A/ko not_active Withdrawn
- 2012-09-07 JP JP2014529893A patent/JP6347745B2/ja not_active Expired - Fee Related
- 2012-09-07 CN CN201280054692.7A patent/CN103917519B/zh not_active Expired - Fee Related
- 2012-09-07 PH PH1/2014/500528A patent/PH12014500528A1/en unknown
- 2012-09-07 US US13/606,444 patent/US8946294B2/en active Active
- 2012-09-07 CA CA2848222A patent/CA2848222C/en active Active
- 2012-09-07 KR KR1020197029814A patent/KR102256613B1/ko active Active
- 2012-09-07 EP EP18190199.2A patent/EP3461810B1/en active Active
- 2012-09-07 DK DK12829775.1T patent/DK2751072T3/en active
- 2012-09-07 BR BR112014005509-2A patent/BR112014005509B1/pt not_active IP Right Cessation
- 2012-09-07 TW TW101132750A patent/TWI586640B/zh not_active IP Right Cessation
- 2012-09-07 ES ES12829775T patent/ES2710212T3/es active Active
- 2012-09-07 CN CN202011607753.0A patent/CN112778157A/zh not_active Withdrawn
- 2012-09-07 AU AU2013201096A patent/AU2013201096B2/en not_active Ceased
- 2012-09-07 RU RU2014111288A patent/RU2629113C2/ru active
- 2012-09-07 MX MX2017005654A patent/MX369690B/es unknown
-
2014
- 2014-03-04 IL IL231310A patent/IL231310B/en active IP Right Grant
- 2014-03-05 MX MX2019009224A patent/MX2019009224A/es unknown
- 2014-03-19 ZA ZA2014/02010A patent/ZA201402010B/en unknown
- 2014-10-21 US US14/519,408 patent/US9604913B2/en not_active Expired - Fee Related
-
2015
- 2015-06-03 PH PH12015501266A patent/PH12015501266B1/en unknown
- 2015-09-07 JP JP2015175584A patent/JP6463237B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-04 US US15/398,236 patent/US10501405B2/en active Active
-
2018
- 2018-04-05 JP JP2018073426A patent/JP6522826B2/ja active Active
-
2019
- 2019-10-28 US US16/665,938 patent/US20200048188A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532038A5 (enExample) | ||
| US20240122925A1 (en) | Shp2 phosphatase inhibitors and methods of making and using the same | |
| CN109789146B (zh) | 趋化因子受体调节剂及其用途 | |
| AU2019356565B2 (en) | Prodrug modulators of the integrated stress pathway | |
| AU2018360854B2 (en) | Modulators of the integrated stress pathway | |
| JP2019514884A (ja) | Ｅｚｈ２インヒビターおよびそれらの使用 | |
| JP2011527683A5 (enExample) | ||
| US20210205277A1 (en) | Modulators of the integrated stress pathway | |
| JP2020517611A5 (enExample) | ||
| JP2013513588A5 (enExample) | ||
| WO2010103312A1 (en) | Hydroxymorpholiness and their use for the treatment of inflammatory disorders and pain | |
| JP7248261B2 (ja) | 癌を処置するための医薬組成物 | |
| JP2021105003A (ja) | 多形体及びキナゾリニル誘導体の調製プロセス | |
| CN105324375A (zh) | 盐酸尼洛替尼的多晶型形式 | |
| JP2009541493A5 (enExample) | ||
| RU2014111288A (ru) | Кристаллический диацилгидразин и его применение | |
| WO2019025588A1 (en) | METHODS OF TREATING ALTERATIONS IN BEHAVIOR | |
| JP2016512198A5 (enExample) | ||
| CN103298777B (zh) | 苯基酮羧酸盐化合物和其药学用途 | |
| JP2015535842A (ja) | ニューロトロフィン模倣化合物の結晶形及びその塩 | |
| EP1326826A1 (de) | Verwendung von aminosäuren zur behandlung von schmerz | |
| EP4429672A1 (en) | Psilocybin and o-acetylpsilocin, salts and solid state forms thereof | |
| CN115427112B (zh) | 2-[(4s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-4h-喹唑啉-4-基]乙酸钾盐 | |
| TW200911757A (en) | Crystalline forms of histone deacetylase inhibitors | |
| JP2009523711A5 (enExample) |